CPA CPA - Immuron Chief Officer
| IMRN Stock | USD 1.88 0.03 1.57% |
Insider
CPA CPA is Chief Officer of Immuron Ltd ADR
| Age | 54 |
| Phone | 61 3 9824 5254 |
| Web | https://www.immuron.com.au |
Immuron Management Efficiency
The company has return on total asset (ROA) of (0.1737) % which means that it has lost $0.1737 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4292) %, meaning that it created substantial loss on money invested by shareholders. Immuron's management efficiency ratios could be used to measure how well Immuron manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| TaiWei Ho | In8bio Inc | 47 | |
| Robert Lutjens | Addex Therapeutics | 56 | |
| Stephen Elledge | Tscan Therapeutics | N/A | |
| Ray Lockard | Tscan Therapeutics | N/A | |
| Wai Lee | Aptorum Group Ltd | 50 | |
| Jean Fourni | Innate Pharma | N/A | |
| Odile Belzunce | Innate Pharma | 44 | |
| Tomasz Kula | Tscan Therapeutics | N/A | |
| Roger MD | Addex Therapeutics | 67 | |
| William Ho | In8bio Inc | 45 | |
| William MBA | Tscan Therapeutics | 54 | |
| Marc Bonneville | Innate Pharma | 64 | |
| JD MBA | Immix Biopharma | N/A | |
| Darren Lui | Aptorum Group Ltd | 42 | |
| Yannis Morel | Innate Pharma | 51 | |
| Dr MedSc | Phio Pharmaceuticals Corp | 68 | |
| Nandan BS | Immix Biopharma | 62 | |
| Gavin MacBeath | Tscan Therapeutics | 54 | |
| Brian JD | Tscan Therapeutics | 55 | |
| Joseph Hazelton | Dyadic International | 48 | |
| Chung Huen | Aptorum Group Ltd | 44 | |
Management Performance
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.17 |
Immuron Ltd ADR Leadership Team
Elected by the shareholders, the Immuron's board of directors comprises two types of representatives: Immuron inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immuron. The board's role is to monitor Immuron's management team and ensure that shareholders' interests are well served. Immuron's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immuron's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| BBus CA, CFO Sec | ||
| Jerry Kanellos, Interim CEO, Chief Operating and Scientific Officer | ||
| Dan Peres, Chief Officer | ||
| Flavio Palumbo, Chief Officer | ||
| David Lyon, Head Marketing |
Immuron Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Immuron a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (1.41) % | ||||
| Operating Margin | (1.32) % | ||||
| Current Valuation | 3.66 M | ||||
| Shares Outstanding | 5.7 M | ||||
| Shares Owned By Institutions | 0.18 % | ||||
| Number Of Shares Shorted | 4.3 K | ||||
| Price To Earning | (2.38) X | ||||
| Price To Book | 1.30 X |
Pair Trading with Immuron
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immuron position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immuron will appreciate offsetting losses from the drop in the long position's value.Moving together with Immuron Stock
Moving against Immuron Stock
| 0.57 | KZR | Kezar Life Sciences | PairCorr |
| 0.53 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.5 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.33 | IKNA | Ikena Oncology | PairCorr |
The ability to find closely correlated positions to Immuron could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immuron when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immuron - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immuron Ltd ADR to buy it.
The correlation of Immuron is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immuron moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immuron Ltd ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Immuron can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immuron Ltd ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immuron. If investors know Immuron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immuron listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immuron Ltd ADR is measured differently than its book value, which is the value of Immuron that is recorded on the company's balance sheet. Investors also form their own opinion of Immuron's value that differs from its market value or its book value, called intrinsic value, which is Immuron's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immuron's market value can be influenced by many factors that don't directly affect Immuron's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immuron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immuron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immuron's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.